Prolia is an injectible drug for postmenopausal women experiencing osteoporosis made by Amgen. It was recently approved as the first drug in a new class of osteoporosis medication by the Food and Drug Administration on Tuesday in the United States. It was approved after being heavily backed by the European Union.
Prolia has been previously approved in all 27 European Union member states plus Norway, Iceland and Liechtenstein and is co-marketed with London-based GlaxoSmithKline.
The said drug is predicted to become a popular drug since people were alarmed about the safety of bisphosphonates. Bisphosphonates and Fosamax, both leading medications for osteoporosis, can lead to cases of jaw necrosis, a severe born deficiency that affects the jaw, maxilla and mandible all parts of the mouth, according to a study.
Prolia is different from other medications for bone health because it blocks the production of cells called osteoclasts that break down the bone.
Prolia as an drug that requires to be injected every six months. In clinical tests, the drug was shown to have reduced vertebral, non-vertebral and hip fractures. However, there can be some side-effects like “back pain, musculoskeletal pain, high cholesterol levels and bladder infections as well as some skin infections and low calcium levels in the blood”.
The wholesale price of Prolia will be $825 per injection.